2023
Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry
Meiklejohn K, Hrones M, Wang M, Prasad M, Cai G, Adeniran A, Gilani S. Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR‐1 (NR4A3) immunohistochemistry. Cytopathology 2023, 34: 219-224. PMID: 36825365, DOI: 10.1111/cyt.13222.Peer-Reviewed Original Research
2020
Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG)
Xu B, Barbieri AL, Bishop JA, Chiosea SI, Dogan S, Di Palma S, Faquin WC, Ghossein R, Hyrcza M, Jo VY, Lewis JS, Lozada JR, Michal M, Pareja FG, Perez-Ordonez B, Prasad ML, Purgina B, Reis-Filho JS, Scognamiglio T, Sebastiao APM, Seethala RR, Skálová A, Smith SM, Tekkeşin MS, Thompson LDR, Wasseman JK, Wenig BM, Weinreb I, Katabi N. Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). The American Journal Of Surgical Pathology 2020, 44: 545-552. PMID: 31917707, PMCID: PMC7437128, DOI: 10.1097/pas.0000000000001431.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaBiomarkers, TumorBiopsyCanadaDNA Mutational AnalysisEuropeGene FusionGenetic Predisposition to DiseaseHumansIn Situ Hybridization, FluorescenceMutationObserver VariationPredictive Value of TestsReal-Time Polymerase Chain ReactionReproducibility of ResultsSalivary Gland NeoplasmsUnited StatesConceptsPapillary architectureIndeterminate featuresPolymorphous adenocarcinomaConsensus diagnosisCribriform adenocarcinomaInterobserver agreementSalivary glandsFair interobserver agreementNeck pathologistHistologic diversityHistologic classificationMorphologic spectrumDiagnostic concordanceSolid patternMolecular alterationsAdenocarcinomaGlomeruloid structuresTumorsLevel of agreementHotspot mutationsClear nucleiModerate agreementExpert pathologistsSuch molecular eventsMolecular signatures
2017
Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon
Xu B, Scognamiglio T, Cohen PR, Prasad ML, Hasanovic A, Tuttle RM, Katabi N, Ghossein RA. Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon. Human Pathology 2017, 65: 133-139. PMID: 28552827, PMCID: PMC5571865, DOI: 10.1016/j.humpath.2017.05.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinomaCarcinoma, PapillaryCell DifferentiationDNA Mutational AnalysisFemaleGenetic Predisposition to DiseaseHumansImmunohistochemistryLymphatic MetastasisMaleMiddle AgedMutationNeoplasm GradingNeoplasms, Unknown PrimaryPhenotypeProto-Oncogene Proteins B-rafRetrospective StudiesThyroid Cancer, PapillaryThyroid Carcinoma, AnaplasticThyroid NeoplasmsConceptsPapillary thyroid carcinomaIdentifiable primary tumorThyroid carcinomaAnaplastic thyroid carcinomaMetastatic diseasePrimary tumorThyroid glandMetastatic papillary thyroid carcinomaEvidence of recurrenceMetastatic nodal diseaseMetastatic thyroid carcinomaTall cell variantBRAF V600E immunohistochemistryThyroid primaryNodal diseaseNeck compartmentDistant metastasisPathologic featuresRetrospective studyAnaplastic carcinomaUnknown causeMost tumorsCarcinomaPatientsThyroid tumorsPathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma
Hardee S, Prasad ML, Hui P, Dinauer CA, Morotti RA. Pathologic Characteristics, Natural History, and Prognostic Implications of BRAFV600E Mutation in Pediatric Papillary Thyroid Carcinoma. Pediatric And Developmental Pathology 2017, 20: 206-212. PMID: 28521635, DOI: 10.1177/1093526616689628.Peer-Reviewed Original ResearchConceptsPapillary thyroid cancerPediatric papillary thyroid cancerPrognostic implicationsPediatric papillary thyroid carcinomaNegative casesBRAF-negative casesBRAF-negative patientsBRAF-positive casesTertiary medical centerAggressive clinical coursePapillary thyroid carcinomaSurgical pathology diagnosisCommon genetic aberrationsNegative patientsAggressive courseClinical coursePathologic characteristicsCase seriesClinical outcomesRetrospective reviewAggressive featuresPediatric casesRecurrence rateRetrospective studySingle institution
2016
NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma
Panaccione A, Chang MT, Carbone BE, Guo Y, Moskaluk CA, Virk RK, Chiriboga L, Prasad ML, Judson B, Mehra S, Yarbrough WG, Ivanov SV. NOTCH1 and SOX10 are Essential for Proliferation and Radiation Resistance of Cancer Stem–Like Cells in Adenoid Cystic Carcinoma. Clinical Cancer Research 2016, 22: 2083-2095. PMID: 27084744, PMCID: PMC4834904, DOI: 10.1158/1078-0432.ccr-15-2208.Peer-Reviewed Original ResearchMeSH KeywordsAC133 AntigenAmyloid Precursor Protein SecretasesAnimalsBiomarkers, TumorCarcinoma, Adenoid CysticCell Line, TumorCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p27Disease Models, AnimalFatty Acid-Binding Protein 7Gene Expression ProfilingHeterograftsHumansLigandsMiceMice, NudeNeoplasm GradingNeoplastic Stem CellsProtein BindingRadiationRadiation ToleranceReceptor, Notch1S-Phase Kinase-Associated ProteinsSOXE Transcription FactorsTumor Cells, CulturedTumor Suppressor ProteinsConceptsCancer stem cellsRibosome biogenesisCancer stem-like cellsStem-like cellsLack of assaysCSC maintenanceMolecular markersNeural differentiationCell deathUncharacterized populationACC therapyΓ-secretase inhibitorCSC viabilityCD133-positive cancer stem cellsStem cellsCell sortingSOX10Essential roleSkp2Notch1P27Kip1Stem propertiesCell culturesImmunomagnetic cell sortingCells
2013
Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas
Ivanov SV, Panaccione A, Nonaka D, Prasad ML, Boyd KL, Brown B, Guo Y, Sewell A, Yarbrough WG. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. British Journal Of Cancer 2013, 109: 444-451. PMID: 23799842, PMCID: PMC3721393, DOI: 10.1038/bjc.2013.326.Peer-Reviewed Original ResearchConceptsBasal-like breast carcinomasAdenoid cystic carcinomaGene signatureBreast cancerSox10 expressionDiagnostic markerBasal-like carcinomasExpression of ERPotential molecular markersSensitive diagnostic markerPotential therapeutic targetBasal cell markersNovel diagnostic markerSalivary adenoid cystic carcinomaMyoepithelial featuresBreast subtypesAdenoid cysticBreast carcinomaCystic carcinomaImmunohistochemical stainingMolecular subtypesHistological similaritiesTherapeutic targetTranscriptional program characteristicDiagnostic significance
2009
IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype
Walter O, Prasad M, Lu S, Quinlan R, Edmiston K, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Human Pathology 2009, 40: 1528-1533. PMID: 19695680, DOI: 10.1016/j.humpath.2009.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastDisease-Free SurvivalFemaleHumansImmunohistochemistryKaplan-Meier EstimateMiddle AgedNeoplasm ProteinsPhenotypeReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesRNA-Binding ProteinsConceptsHuman epidermal growth factor receptor 2Invasive mammary carcinomaInvasive ductal carcinomaIMP3 expressionNovel biomarkersDuctal carcinomaProgesterone receptorMammary carcinomaBreast cancerEstrogen receptorAggressive phenotypeEpidermal growth factor receptor 2Triple-negative breast cancerDisease-free survivalBiologic prognostic factorsGrowth factor receptor 2Lymph node metastasisInsulin-like growth factor II mRNABasal-like carcinomasGrowth factor II mRNABasal epithelial markersNegative breast cancerBreast cancer casesFactor receptor 2Mouse monoclonal antibodyInsulin-Like Growth Factor mRNA Binding Protein 3 (IMP3) is Differentially Expressed in Benign and Malignant Follicular Patterned Thyroid Tumors
Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A. Insulin-Like Growth Factor mRNA Binding Protein 3 (IMP3) is Differentially Expressed in Benign and Malignant Follicular Patterned Thyroid Tumors. Endocrine Pathology 2009, 20: 149-157. PMID: 19449140, DOI: 10.1007/s12022-009-9079-x.Peer-Reviewed Original ResearchConceptsHürthle cell carcinomaPapillary thyroid carcinomaHürthle cell adenomaFollicular carcinomaGraves' diseaseHashimoto's thyroiditisColloid nodulesFollicular adenomaIMP3 expressionThyroid carcinomaStrong stainingInsulin-like growth factor mRNAThyroid lesionsProtein 3Conventional papillary thyroid carcinomaPathologic tumor characteristicsInsulin-like growth factor IIResidual thyroid tissueSurgical pathology archivesBinding protein 3Thyroid follicular lesionsGrowth factor IIGrowth factor mRNATumor characteristicsUterine cervix
2001
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles
Huang Y, Prasad M, Lemon W, Hampel H, Wright F, Kornacker K, LiVolsi V, Frankel W, Kloos R, Eng C, Pellegata N, de la Chapelle A. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proceedings Of The National Academy Of Sciences Of The United States Of America 2001, 98: 15044-15049. PMID: 11752453, PMCID: PMC64980, DOI: 10.1073/pnas.251547398.Peer-Reviewed Original ResearchConceptsNumerous additional genesExtracellular matrix proteinsTranscriptase-PCRFunction-related proteinsAdditional genesSpecific molecular changesGene expressionDNA arraysExpression profilesTumor suppressorMatrix proteinsMolecular biologyGenesMolecular pathwaysReverse transcriptase-PCRPTC tissuesCITED1Molecular changesProteinODZ1Concordant expressionHigh expressionNormal thyroid tissueExpressionPapillary thyroid carcinoma
1999
Microinvasive carcinoma of the breast: can it be diagnosed reliably and is it clinically significant?
Hoda, Prasad, Moore, Hoda, Giri. Microinvasive carcinoma of the breast: can it be diagnosed reliably and is it clinically significant? Histopathology 1999, 35: 468-470. PMID: 10583563, DOI: 10.1046/j.1365-2559.1999.0820a.x.Commentaries, Editorials and LettersConceptsDefinition of microinvasionPresence of microinvasionSitu breast carcinomaUtility of immunohistochemistryMicroinvasive carcinomaHistological featuresReparative changesBreast carcinomaClinical significanceSitu carcinomaMicroinvasionCarcinomaFurther treatmentCommon problemImmunohistochemistryBreastDiagnosis